Subscribe or Manage Preferences

Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA

Rheumatology Practice Management December 2017 Vol 5 No 5 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

The efficacy and safety of sarilu­mab, a human monoclonal antibody blocking the interleukin-6 receptor alpha, were evaluated for treatment of rheumatoid arthritis (RA) in 3 clinical trials, including the MOBILITY trial. The phase 3, 52-week MOBILITY study demonstrated that subcutaneous sarilumab (150 mg or 200 mg every 2 weeks [q2w]) plus methotrexate (MTX) achieved clinical and radiographic efficacy in adults with active, moderate-to-severe RA and inadequate response to MTX. The current analysis examined differences in the mean duration of response in the MOBILITY study based on 5 different definitions of duration of response. The co-primary end points of the MOBILITY trial were proportion of patients achieving American College of Rheumatology (ACR) response at week 24, change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at week 16, and change from baseline in van der Heijde–modified total Sharp score at week 52.

The 5 different definitions of duration of response were: (1) first response to loss of response; (2) longest response; (3) responder weeks; (4) responder weeks percent; and (5) sustained response based on binary analysis (yes/no) of whether the response was maintained until the end of the double-blind period. Duration of response was measured for 20% improvement in ACR improvement criteria (ACR20), improvement in HAQ-DI of ≥0.3 units, Clinical Disease Activity Index (CDAI; ≤2.8), Simplified Disease Activity Index (SDAI; ≤3.3), and Disease Activity Score 28–C-reactive protein (DAS28-CRP; <2.6). Patients included in these analyses must have achieved a response at any point during the study and been considered responders. If patients had a missing value or took rescue medication, they were considered nonresponders for those specific visits.

Regardless of response definition used for ACR20, HAQ-DI, and DAS28-CRP, patients who achieved a response at any point with sarilumab 150 mg or 200 mg q2w plus MTX on the MOBILITY trial had significantly longer duration of response compared with those treated with placebo plus MTX. Whereas patients receiving sarilumab (150 mg or 200 mg) achieved numerically larger differences in CDAI and SDAI versus placebo; these differences did not reach a nominal P <.05. Compared with placebo, the number of responder weeks was also greater (nominal P <.0001) for patients who received sarilumab 150-mg and 200-mg treatment for ACR20 (61.0% and 65.0% vs 44.8%, respectively), HAQ-DI improvement (57.8% and 59.7% vs 44.4%, respectively), and DAS28-CRP (44.5% and 49.4% vs 29.4%, respectively). In terms of sustainability of response, significantly more sarilumab-treated patients showed responses by both ACR20 and HAQ-DI, regardless of whether they achieved response at week 12 or 24.

This analysis showed that patients treated with either dose of sarilumab plus MTX achieved longer duration of response versus those treated with placebo plus MTX, regardless of the definition of response used.

Source: Genovese MC, Mangan EK, Kimura T, et al. Duration of response in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 2479.

Related Items
Efficacy and Safety of Switching from Adalimumab to Sarilumab
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab + csDMARDs Effective Regardless of Baseline Disease Activity in RA Patients with Inadequate Response to TNF Inhibitors
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
An Updated Integrated Safety Analysis of Baricitinib for the Treatment of Moderate-to-Severe RA
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab Efficacy Maintained or Improved in Previously Treated Patients with RA
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Tofacitinib with and without MTX and Adalimumab with MTX Improves PROs in Patients with RA
Rheumatology Practice Management December 2017 Vol 5 No 5 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: January 15, 2018
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search